Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 43 min ago
Peer-reviewedLicence not statedHepatology (Baltimore, Md.)

Therapies for Alcohol Use Disorder in Alcohol-associated Hepatitis Clinical Trials: Integrated Trial Design with a Composite Clinical Outcome as the Primary Endpoint

  • Srinivasan Dasarathy1
  • Victor M. Karpyak2
  • Juan Pablo Arab3
  • Ashwani K. Singal4
  • Douglas A. Simonetto5
  • Sherwood Brown6
  • Wanzhu Tu7
  • Samer Gawrieh8
8 affiliations
  1. 1Department of Gastroenterology and Hepatology, and Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio
  2. 2Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota
  3. 3Department of Gastroenterology, Virginia Commonwealth University, Richmond, Virginia
  4. 4University of Louisville School of Medicine, Louisville, Kentucky
  5. 5Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester; Minnesota
  6. 6Division of Clinical Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas
  7. 7Department of Biostatistics & Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana
  8. 8Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana
Read full textDOICite

Related

  1. Identification of hepatitis B virus-associated membrane proteins as prognostic biomarkers for hepatocellular carcinoma based on retrospective analysis of integrated membrane proteomics
    Zichen Liu, Jiaming Wan, Guoli Deng +5
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Impact of opioid agonist therapies on non-fatal and fatal overdose: treatment patterns among individuals with opioid use disorder in Ontario, Canada
    Kenneth Lee, Vincent Lam, Jennifer Nicolle +4
    Frontiers in public healthPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  3. Acupuncture-related therapies as an adjunct to opioid agonist therapy during active dose reduction in adults with opioid use disorder: protocol for a scoping review
    Chen Chen, Xiao-Juan Li, Baochao Fan +4
    BMJ OpenPeer-reviewedCC BY-NC 4.0General medicineCrossref
  4. 208 Development of an integrated in vitro and in vivo platform for rapid evaluation of in vivo CAR-T therapies
    Jun Li, Xiang Gao, HongYan Sun +4
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  5. Cancer-related pain management update in 2025: refining established therapies and expanding toward integrated multimodal and longitudinal management.
    Yufeng Li, Jing Cang, Fang Fang
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC

Cite

BibTeXRIS
BibTeX
@article{dasarathy2026therapies,
  title = {{Therapies for Alcohol Use Disorder in Alcohol-associated Hepatitis Clinical Trials: Integrated Trial Design with a Composite Clinical Outcome as the Primary Endpoint}},
  author = {Srinivasan Dasarathy and Victor M. Karpyak and Juan Pablo Arab and Ashwani K. Singal and Douglas A. Simonetto and Sherwood Brown and Wanzhu Tu and Samer Gawrieh},
  journal = {Hepatology (Baltimore, Md.)},
  year = {2026},
  month = sep,
  doi = {10.1097/hep.0000000000001878},
  url = {https://doi.org/10.1097/hep.0000000000001878},
}
RIS
TY  - JOUR
TI  - Therapies for Alcohol Use Disorder in Alcohol-associated Hepatitis Clinical Trials: Integrated Trial Design with a Composite Clinical Outcome as the Primary Endpoint
AU  - Srinivasan Dasarathy
AU  - Victor M. Karpyak
AU  - Juan Pablo Arab
AU  - Ashwani K. Singal
AU  - Douglas A. Simonetto
AU  - Sherwood Brown
AU  - Wanzhu Tu
AU  - Samer Gawrieh
PY  - 2026
DA  - 2026/09/28
JO  - Hepatology (Baltimore, Md.)
DO  - 10.1097/hep.0000000000001878
UR  - https://doi.org/10.1097/hep.0000000000001878
SN  - 0270-9139
SN  - 1527-3350
ER  -